Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Fresh Tracks Therapeutics Inc (Fresh Tracks Therapeutics) formerly Brickell Biotech Inc, discovers and develops pharmaceutical products for inflammatory, autoimmune and other debilitating diseases. The company's pipeline products include FRTX-02 treats autoimmune and inflammatory diseases; FRTX-10 targets autoimmune, inflammatory, and rare genetic diseases; next-generation kinase inhibitors is for the treatment of autoimmune, inflammatory, and other debilitating diseases; FRTX-03 for autoimmune immunology. The company partners with pharmaceutical, biotechnology companies, government agencies and research institutions. Fresh Tracks Therapeutics is headquartered in Boulder, Colorado, the US.
Headquarters
United States of America
Address
2000 Central Avenue, Suite 100, Boulder, Colorado, 80301
Website
www.frtx.com
Telephone
1 720 5054755
No of Employees
4
Industry
Pharmaceuticals and Healthcare
Revenue (2023)
$8.0M
Fresh Tracks Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| FRTX-02: Autoimmune and Inflammatory Diseases |
| FRTX-10: Autoimmune, Inflammatory, and Rare Genetic Diseases |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Fresh Tracks Therapeutics Inc | Harpoon Therapeutics Inc | Azitra Inc | Cogent Biosciences Inc | LEO Pharma Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Boulder | San Francisco | Branford | Waltham | Madison |
| State/Province | Colorado | California | Connecticut | Massachusetts | New Jersey |
| No. of Employees | 4 | 53 | 12 | 205 | - |
| Entity Type | Private | Private | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Reginald Hardy | Co-Founder; Chairman | Executive Board | - | - |
| Andrew Sklawer | Chief Executive Officer; Co-Founder; President | Senior Management | - | - |
| Bert Marchio | Chief Financial Officer | Senior Management | - | - |
| Deepak Chadha | Chief Research and Development (R&D) Officer; Chief Operating Officer | Senior Management | - | - |
| Aaron Fox-Collis | Vice President - Finance; Chief Accounting Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer